BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...firm's twelfth and leaves it with over $1.2 billion under management. Abingworth Management Ltd., London, U.K. Allison Johnson Abingworth Management...
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

...Nouscom AG and participation in a series A for cough company Attenua Inc. Allison Johnson, Staff Writer Abingworth Management...
BioCentury | Jul 9, 2018
Financial News

Abingworth closes BioVentures VII fund at $315M

...BioVentures VII is the firm's twelfth and leaves it with over $1.2 billion under management. Allison Johnson Abingworth Management...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Cambridge Innovation Capital, Vertex Ventures HC Bicyclic peptides Cancer Nouscom AG (Switzerland) $48.7 Series B Abingworth Management...
BioCentury | May 17, 2018
Finance

Europe’s piece of the pie

...to create defective viral particles that mimic and outcompete infectious viruses University of Warwick Infectious Abingworth Management...
...its innovative path. I think Belgium, Germany and Sweden are the emerging leaders,” he said. Abingworth Management...
...and options for exit,” he said. Companies and Institutions Mentioned Abarceo Pharma AB, Malmö, Sweden Abingworth Management...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Series A and B $134.3 (A) Celgene Corp. , SR One, New Enterprise Associates , Abingworth Management...
BioCentury | Sep 19, 2016
Financial News

GammaDelta Therapeutics completes venture financing

...London, U.K. Business: Cancer Date completed: 2016-09-15 Type: Venture financing Raised: Not disclosed Investors: Abingworth Management...
BioCentury | Sep 15, 2016
Product R&D

Enter GammaDelta

Lauren Martz, Senior Writer Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many...
BioCentury | Jul 11, 2016
Finance

Ground up

...anybody expected to lose money in the likes of Regeneron," said Kurt von Emster of Abingworth Management...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...company valued at less than $250 million. On his 3Q16 calendar, Kurt von Emster of Abingworth Management...
Items per page:
1 - 10 of 159
BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...firm's twelfth and leaves it with over $1.2 billion under management. Abingworth Management Ltd., London, U.K. Allison Johnson Abingworth Management...
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

...Nouscom AG and participation in a series A for cough company Attenua Inc. Allison Johnson, Staff Writer Abingworth Management...
BioCentury | Jul 9, 2018
Financial News

Abingworth closes BioVentures VII fund at $315M

...BioVentures VII is the firm's twelfth and leaves it with over $1.2 billion under management. Allison Johnson Abingworth Management...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Cambridge Innovation Capital, Vertex Ventures HC Bicyclic peptides Cancer Nouscom AG (Switzerland) $48.7 Series B Abingworth Management...
BioCentury | May 17, 2018
Finance

Europe’s piece of the pie

...to create defective viral particles that mimic and outcompete infectious viruses University of Warwick Infectious Abingworth Management...
...its innovative path. I think Belgium, Germany and Sweden are the emerging leaders,” he said. Abingworth Management...
...and options for exit,” he said. Companies and Institutions Mentioned Abarceo Pharma AB, Malmö, Sweden Abingworth Management...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Series A and B $134.3 (A) Celgene Corp. , SR One, New Enterprise Associates , Abingworth Management...
BioCentury | Sep 19, 2016
Financial News

GammaDelta Therapeutics completes venture financing

...London, U.K. Business: Cancer Date completed: 2016-09-15 Type: Venture financing Raised: Not disclosed Investors: Abingworth Management...
BioCentury | Sep 15, 2016
Product R&D

Enter GammaDelta

Lauren Martz, Senior Writer Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many...
BioCentury | Jul 11, 2016
Finance

Ground up

...anybody expected to lose money in the likes of Regeneron," said Kurt von Emster of Abingworth Management...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...company valued at less than $250 million. On his 3Q16 calendar, Kurt von Emster of Abingworth Management...
Items per page:
1 - 10 of 159